Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 South African Medical Research Council Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, Univer- sity of Cape Town, CapeTown, South Africa; 2Department of Psychology and Department of Psychiatry and Biobehavioral Sciences, University of Cali- fornia, Los Angeles (UCLA), Los Angeles, CA, USA; 3 Department of Psychiatry, Emory University, Atlanta, GA, USA; 4 Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, and Southern Health NHS Foundation Trust, Southampton, UK; 5 School of Life and Medical Sciences, University of Hertfordshire, and Hertfordshire Partnership University NHS Foundation Trust, Hatfield, UK; 6 University of Cambridge Clinical Medical School, Cambridge, UK; 7 Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; 8 Develop- mental Psychology, Department of Psychology, Rijksuniversiteit Groningen, Groningen, The Netherlands; 9 Department of Psychiatry, University of Cam- pania “L.Vanvitelli”, Naples, Italy
Список исп. литературыСкрыть список
1. Baxter AJ, Scott KM, Vos T et al. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med 2013;43:897-910.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington: American Psychiatric Association, 1980.
3. Liebowitz MR, Schneier F, Campeas R et al. Phenelzine vs. atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
4. Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008;371:1115-25.
5. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Dialogues Clin Neurosci 2017;19:93-107.
6. Maj M, Stein DJ, Parker G et al. The clinical characterization of the adult patient with depression aimed at personalization of management. World Psychiatry 2020;19:269-93.
7. Ressler KJ. Translating across circuits and genetics toward progress in fear and anxiety-related disorders. Am J Psychiatry 2020;177:214-22.
8. Chamberlain SR, Solly JE, Hook RW et al. Cognitive inflexibility in OCD and related disorders. Curr Top Behav Neurosci (in press).
9. National Institute of Mental Health. Research Domain Criteria initiative. www.nimh.nih.gov.
10. Stein DJ, Craske MG, Friedman MJ et al. Meta-structure issues for the DSM-5: how do anxiety disorders, obsessive-compulsive and related disorders, post-traumatic disorders, and dissociative disorders fit together? Curr Psy-chiatry Rep 2011;13:248-50.
11. Bandelow B, Baldwin D, Abelli M et al. Biological markers for anxiety disorders, OCD and PTSD: a consensus statement. Part II: Neurochemistry,neurophysiology and neurocognition. World J Biol Psychiatry 2017;18:162-214.
12. Strawn JR, Levine A. Treatment response biomarkers in anxiety disorders: from neuroimaging to neuronally-derived extracellular vesicles and beyond. Biomark Neuropsychiatry 2020;3:100024.
13. Lueken U, Zierhut KC, Hahn T et al. Neurobiological markers predicting treatment response in anxiety disorders: a systematic review and implications for clinical application. Neurosci Biobehav Rev 2016;66:143-62.
14. Bosman RC, ten Have M, de Graaf R et al. Prevalence and course of subthreshold anxiety disorder in the general population: a three-year follow-up study. J Affect Disord 2019;247:105-13.
15. Stein DJ, Szatmari P, Gaebel W et al. Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Med 2020;18:21.
16. Brewin CR, Cloitre M, Hyland P et al. A review of current evidence regarding the ICD-11 proposals for diagnosing PTSD and complex PTSD. Clin Psychol Rev 2017;58:1-15.
17. Reed GM, First MB, Kogan CS et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019;18:3-19.
18. Craske MG. Anxiety disorders: psychological approaches to theory and treatment. Boulder: Westview, 1999.
19. Grillon C. Models and mechanisms of anxiety: evidence from startle studies.Psychopharmacology 2008;199:421-37.
20. Craske MG, Rauch SL, Ursano R et al. What is an anxiety disorder? Depress Anxiety 2009;26:1066-85.
21. Fanselow MS, Lester LS. A functional behavioristic approach to aversively motivated behavior: predatory imminence as a determinant of the topography of defensive behavior. In: Bolles RC, Beecher MD (eds). Evolution and learning. Mahwah: Erlbaum, 1988:185-211.
22. Mobbs D, Hagan CC, Dalgleish T et al. The ecology of human fear: survival optimization and the nervous system. Front Neurosci 2015;9:55.
23. Mobbs D. The ethological deconstruction of fear(s). Curr Opin Behav Sci 2018;24:32-7.
24. Adhikari A. Distributed circuits underlying anxiety. Front Behav Neurosci 2014;8:112.
25. Kim S-Y, Adhikari A, Lee SY et al. Diverging neural pathways assemble a behavioural state from separable features in anxiety. Nature 2013;496:219-23.
26. Mobbs D, Petrovic P, Marchant JL et al. When fear is near: threat imminence elicits prefrontal-periaqueductal gray shifts in humans. Science 2007;317:1079-83.
27. Mobbs D, Headley DB, Ding W et al. Space, time, and fear: survival computations along defensive circuits. Trends Cogn Sci 2020;24:228-41.
28. Lang PJ. A bio-informational theory of emotional imagery. Psychophysiology 1979;16:495-512.
29. Williams SL, Kinney PJ, Harap ST et al. Thoughts of agoraphobic people during scary tasks. J Abnorm Psychol 1997;106:511-20.
30. Lang PJ, Levin DN, Miller GA et al. Fear behavior, fear imagery, and the psychophysiology of emotion: the problem of affective response integration. J Abnorm Psychol 1983;92:276-306.
31. Kircanski K, Craske MG, Epstein AM et al. Subtypes of panic attacks: a critical review of the empirical literature. Depress Anxiety 2009;26:878-87.
32. First MB, Williams JBW, Karg RS et al. Structured Clinical Interview for DSM5 Disorders: SCID-5-CV: Clinician Version. Washington: American Psychiatric Publishing, 2016.
33. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl. 20):22-33.
34. Robins LN, Wing J, Wittchen HU et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry 1988;45:1069-77.
35. Brown TA, Barlow DH. Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5), Adult and Lifetime Version: Clinician Manual. Oxford:Oxford University Press, 2014.
36. Lochner C, Stein DJ. Obsessive-compulsive spectrum disorders in obsessive-compulsive disorder and other anxiety disorders. Psychopathology 2010;43:389-96.
37. Alonso J, Liu Z, Evans-Lacko S et al. Treatment gap for anxiety disorders is global: results of the World Mental Health Surveys in 21 countries. Depress Anxiety 2018;35:195-208.
38. Spitzer RL, Kroenke K, Williams JBW et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7.
39. Plummer F, Manea L, Trepel D et al. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry 2016;39:24-31.
40. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
41. Campbell-Sills L, Norman SB, Craske MG et al. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord 2009;112:92-101.
42. Somerville S, Byrne SL, Dedman K et al. Detecting the severity of perinatal anxiety with the Perinatal Anxiety Screening Scale (PASS). J Affect Disord 2015;186:18-25.
43. Kotov R, Perlman G, Gámez W et al. The structure and short-term stability of the emotional disorders: a dimensional approach. Psychol Med 2015;45:1687-98.
44. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013.
45. Lebeau RT, Glenn DE, Hanover LN et al. A dimensional approach to measuring anxiety for DSM-5: dimensional measurement of anxiety for DSM-5. Int J Methods Psychiatr Res 2012;21:258-72.
46. Niles AN, Lebeau RT, Liao B et al. Dimensional indicators of generalized anxiety disorder severity for DSM-V. J Anxiety Disord 2012;26:279-86.
47. Knappe S, Klotsche J, Strobel A et al. Dimensional anxiety scales for DSM-5: sensitivity to clinical severity. Eur Psychiatry 2013;28:448-56.
48. LeBeau RT, Mischel ER, Simpson HB et al. Preliminary assessment of obsessive-compulsive spectrum disorder scales for DSM-5. J Obsessive Compuls Relat Disord 2013;2:114-8.
49. Knappe S, Klotsche J, Heyde F et al. Test-retest reliability and sensitivity to change of the dimensional anxiety scales for DSM-5. CNS Spectr 2014;19:256-67.
50. LeBeau R, Mischel E, Resnick H et al. Dimensional assessment of posttraumatic stress disorder in DSM-5. Psychiatry Res 2014;218:143-7.
51. LeBeau R, Bögels S, Möller E et al. Integrating dimensional assessment and categorical diagnosis in DSM-5: the benefits and challenges of the paradigm shift for the anxiety disorders. Psychopathol Rev 2015;a2:83-99.
52. LeBeau RT, Mesri B, Craske MG. The DSM-5 social anxiety disorder severity scale: evidence of validity and reliability in a clinical sample. Psychiatry Res 2016;244:94-6.
53. Meyer TJ, Miller ML, Metzger RL et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990;28:487-95.
54. Storch EA, Rasmussen SA, Price LH et al. Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale, 2nd ed. Psychol Assess 2010;22:223-32.
55. Rapee RM, Craske MG, Barlow DH. Assessment instrument for panic disorder that includes fear of sensation-producing activities: the Albany Panic and Phobia Questionnaire. Anxiety 1994;1:114-22.
56. Chambless DL, Caputo GC, Jasin SE et al. The Mobility Inventory for Agoraphobia. Behav Res Ther 1985;23:35-44.
57. Shear MK, Brown TA, Barlow DH et al. Multicenter Collaborative Panic Disorder Severity Scale. Am J Psychiatry 1997;154:1571-5.
58. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995;10:73-82.
59. Blevins CA, Weathers FW, Davis MT et al. The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress 2015;28:489-98.
60. Weathers FW, Bovin MJ, Lee DJ et al. The Clinician-Administered PTSD Scale for DSM–5 (CAPS-5): development and initial psychometric evaluation in military veterans. Psychol Assess 2018;30:383-95.
61. Turner SM, Stanley MA, Beidel DC et al. The social phobia and anxiety inventory: construct validity. J Psychopathol Behav Assess 1989;11:221-34.
62. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73.
63. Geer JH. The development of a scale to measure fear. Behav Res Ther 1965;3: 45-53.
64. Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008;69:621-32.
65. Cuijpers P, Cristea IA, Karyotaki E et al. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence. World Psychiatry 2016;15:245-58.
66. Reid JE, Laws KR, Drummond L et al. Cognitive behavioural therapy with exposure and response prevention in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of randomised controlled trials. Compr Psychiatry 2021;106:152223.
67. National Institute for Care and Health Excellence. Anxiety disorders. Quality standard. London: National Institute for Care and Health Excellence, 2014.
68. Barlow DH, Harris BA, Eustis EH et al. The unified protocol for transdiagnostic treatment of emotional disorders. World Psychiatry 2020;19:245-6.
69. Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:403-39.
70. Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic-and symptom-guided drug selection. J Clin Psychiatry 2008;69:959-65.
71. Waszczuk MA, Zimmerman M, Ruggero C et al. What do clinicians treat: diagnoses or symptoms? The incremental validity of a symptom-based, dimensional characterization of emotional disorders in predicting medication prescription patterns. Compr Psychiatry 2017;79:80-8.
72. Craske MG. Honoring the past, envisioning the future: ABCT’s 50th Anniversary Presidential Address. Behav Ther 2018;49:151-64.
73. Holmes EA, Ghaderi A, Harmer CJ et al. The Lancet Psychiatry Commission on psychological treatments research in tomorrow’s science. Lancet Psychiatry 2018;5:237-86.
74. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
75. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301.
76. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 2014;28:835-54.
77. Li X, Zhu L, Zhou C et al. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: a meta-analysis. PLoS One 2018;13:e0194501.
78. Stein DJ, Khoo J-P, Picarel-Blanchot F et al. Efficacy of agomelatine 25-50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: a meta-analysis of three placebo-controlled studies. Adv Ther 2021;38:1567-83.
79. Stein D, Andersen HF, Goodman W. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005;17:71-5.
80. Bloch MH, Landeros-Weisenberger A, Rosario MC et al. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry 2008;165:1532-42.
81. Kim D, Ryba NL, Kalabalik J et al. Critical review of the use of second-generation antipsychotics in obsessive-compulsive and related disorders. Drugs R D 2018;18:167-89.
82. Eisen JL, Phillips KA, Baer L et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry 1998;155:102-8.
83. Leckman JF, Denys D, Simpson HB et al. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety 2010;27:507-27.
84. Lee EB, Goodman WK, Schneider SC et al. Parent-led behavioral intervention for a treatment-refusing adult with obsessive-compulsive disorder with poor insight and extreme family accommodation. J Psychiatr Pract 2020;26:149-52.
85. de Avila RCS, do Nascimento LG, de Moura Porto RL et al. Level of insight in patients with obsessive-compulsive disorder: an exploratory comparative study between patients with “good insight” and “poor insight”. Front Psychiatry 2019;10:413.
86. Martino D, Pringsheim TM, Cavanna AE et al. Systematic review of severity scales and screening instruments for tics: critique and recommendations. Mov Disord 2017;32:467-73.
87. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993;50:306-17.
88. Okuro RT, Freire RC, Zin WA et al. Panic disorder respiratory subtype: psychopathology and challenge tests – an update. Braz J Psychiatry 2020;42:420-30.
89. Charney DS. Psychobiologic mechanisms of posttraumatic stress disorder. Arch Gen Psychiatry 1993;50:295-305.
90. Bryant RA. Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges. World Psychiatry 2019;18:259-69.
91. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 2006;1:CD002795.
92. Lanius RA, Vermetten E, Loewenstein RJ et al. Emotion modulation in PTSD: clinical and neurobiological evidence for a dissociative subtype. Am J Psychiatry 2010;167:640-7.
93. Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986;174:727-35.
94. Carlson EB, Putnam FW. An update of the Dissociative Experience Scale. Dissociation 1993;6:16-27.
95. Resick PA, Suvak MK, Johnides BD et al. Impact of dissociation on PTSD treatment with cognitive processing therapy. Depress Anxiety 2012;29:718-30.
96. Karatzias T, Murphy P, Cloitre M et al. Psychological interventions for ICD-11 complex PTSD symptoms: systematic review and meta-analysis. Psychol Med 2019;49:1761-75.
97. Heimberg RG, Hofmann SG, Liebowitz MR et al. Social anxiety disorder in DSM-5. Depress Anxiety 2014;31:472-9.
98. Steenen SA, van Wijk AJ, van der Heijden GJMG et al. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol 2016;30:128-39.
99. Stein D, Stein M, Goodwin W et al. The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and in less generalized social anxiety disorder. Psychopharmacology 2001;158:267-72.
100. Marks I. Blood-injury phobia: a review. Am J Psychiatry 1988;145:1207-13.
101. Ritz T, Meuret AE, Ayala ES. The psychophysiology of blood-injection-injury phobia: looking beyond the diphasic response paradigm. Int J Psychophysiol 2010;78:50-67.
102. McMurtry CM, Noel M, Taddio A et al. Interventions for individuals with high levels of needle fear: systematic review of randomized controlled trials and quasi-randomized controlled trials. Clin J Pain 2015;31:S109-23.
103. Shepherd N, Parker C. Depression in adults: recognition and management. Pharm J 2017;9:4.
104. Reeves P, Szewczyk Z, Proudfoot J et al. Economic evaluations of stepped models of care for depression and anxiety and associated implementation strategies: a review of empiric studies. Int J Integrat Care 2019;19:1-10.
105. Cross SP, Hickie I. Transdiagnostic stepped care in mental health. Public Health Res Pract 2017;27:2721712.
106. Boswell JF, Kraus DR, Miller SD et al. Implementing routine outcome monitoring in clinical practice: benefits, challenges, and solutions. Psychother Res 2015;25:6-19.
107. Scott K, Lewis CC. Using measurement-based care to enhance any treatment. Cogn Behav Pract 2015;22:49-59.
108. Craske MG, Roy-Byrne PP, Stein MB et al. Treatment for anxiety disorders: efficacy to effectiveness to implementation. Behav Res Ther 2009;47:931-7.
109. Romba C, Lavigne J, Walkup J et al. Measurement-based care in the treatment of anxiety. Child Adolesc Psychiatr Clin 2020;29:645-61.
110. Bandelow B, Baldwin DS, Dolberg OT et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006;67:1428-34.
111. Stein DJ, Bandelow B, Dolberg OT et al. Anxiety symptom severity and functional recovery or relapse. Ann Clin Psychiatry 2009;21:81-8.
112. National Collaborating Centre for Mental Health (UK). Generalised anxiety disorder in adults: management in primary, secondary and community care. Leicester: British Psychological Society, 2011.
113. Storch EA, De Nadai AS, Conceição do Rosário M et al. Defining clinical severity in adults with obsessive-compulsive disorder. Compr Psychiatry 2015;63:30-5.
114. Koran LM, Hanna GL, Hollander E et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007;164:5-53.
115. Hendriks L, de Kleine RA, Broekman TG et al. Intensive prolonged exposure therapy for chronic PTSD patients following multiple trauma and multiple treatment attempts. Eur J Psychotraumatol 2018;9:1425574.
116. Rauch SAM, Yasinski CW, Post LM et al. An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: retention, predictors, and patterns of change. Psychol Serv (in press).
117. Post LM, Held P, Smith DL et al. Impact of intensive treatment programs for posttraumatic stress disorder on suicidal ideation in veterans and service members. Psychol Serv (in press).
118. Chamberlain SR, Blackwell AD, Fineberg NA et al. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 2005;29:399-419.
119. Bora E. Meta-analysis of neurocognitive deficits in unaffected relatives of obsessive-compulsive disorder (OCD): comparison with healthy controls and patients with OCD. Psychol Med 2020;50:1257-66.
120. de Lima Muller J, Torquato KI, Manfro GG et al. Executive functions as a potential neurocognitive endophenotype in anxiety disorders: a systematic review considering DSM-IV and DSM-5 diagnostic criteria classification. Dement Neuropsychol 2015;9:285-94.
121. Eng GK, Sim K, Chen S-HA. Meta-analytic investigations of structural grey matter, executive domain-related functional activations, and white matter diffusivity in obsessive compulsive disorder: an integrative review. Neurosci Biobehav Rev 2015;52:233-57.
122. Mataix-Cols D, do Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005;162:228-38.
123. Ferreri F, Lapp LK, Peretti C-S. Current research on cognitive aspects of anxiety disorders. Curr Opin Psychiatry 2011;24:49-54.
124. Fullana MA, Abramovitch A, Via E et al. Diagnostic biomarkers for obsessive-compulsive disorder: a reasonable quest or ignis fatuus? Neurosci Biobehav Rev 2020;118:504-13.
125. Dittrich WH, Johansen T, Fineberg NA. Cognitive Assessment Instrument of Obsessions and Compulsions (CAIOC-13) – A new 13-item scale for evaluating functional impairment associated with OCD. Psychiatry Res 2011;187:283-90.
126. Fineberg NA, Dell’Osso B, Albert U et al. Early intervention for obsessivecompulsive disorder: an expert consensus statement. Eur Neuropsycho-pharmacol 2019;29:549-65.
127. D’Alcante CC, Diniz JB, Fossaluza V et al. Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 2012;39:310-7.
128. Hofmann SG, Wu JQ, Boettcher H et al. Effect of pharmacotherapy for anxiety disorders on quality of life: a meta-analysis. Qual Life Res 2014;23:1141-53.
129. Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: ameta-analytic review. Clin Psychol Rev 2007;27:572-81.
130. Coluccia A, Fagiolini A, Ferretti F et al. Adult obsessive-compulsive disorder and quality of life outcomes: a systematic review and meta-analysis. Asian J Psychiatry 2016;22:41-52.
131. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996;11:89-95.
132. Endicott J, Nee J, Harrison W et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6.
133. McHorney CA, Johne W, Anastasiae R. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-63.
134. Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Appl Health Econ Health Policy 2017;15:127-37.
135. Frisch MB, Cornell J, Villanueva M et al. Clinical validation of the Quality of Life Inventory. A measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess 1992;4:92-101.
136. Kazis LE, Selim A, Rogers W et al. Dissemination of methods and results from the Veterans Health Study: final comments and implications for future monitoring strategies within and outside the Veterans Healthcare System. J Ambul Care Manag 2006;29:310-9.
137. National Collaborating Centre for Mental Health (UK). Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. Leicester: British Psychological Society, 2006.
138. Watson D, Naragon-Gainey K. Personality, emotions, and the emotional disorders. Clin Psychol Sci 2014;2:422-42.
139. Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. J Abnorm Psychol 1991;100:316-36.
140. Khoo S, Stanton K, Clark LA et al. Facet-level personality relations of the symptom dimensions of the tripartite model. J Psychopathol Behav Assess 2020;42:160-77.
141. Sauer-Zavala S, Wilner JG, Barlow DH. Addressing neuroticism in psychological treatment. Personal Disord 2017;8:191-8.
142. Stein MB, Chen C-Y, Jain S et al. Genetic risk variants for social anxiety. Am J Med Genet 2017;174:120-31.
143. Rosellini AJ, Brown TA. The NEO Five-Factor Inventory: latent structure and relationships with dimensions of anxiety and depressive disorders in a large clinical sample. Assessment 2011;18:27-38.
144. Diedrich A, Voderholzer U. Obsessive-compulsive personality disorder: a current review. Curr Psychiatry Rep 2015;17:2.
145. Naragon-Gainey K, Simms LJ. Three-way interaction of neuroticism, extraversion, and conscientiousness in the internalizing disorders: evidence of disorder specificity in a psychiatric sample. J Res Personal 2017;70:16-26.
146. Javaras KN, Schaefer SM, van Reekum CM et al. Conscientiousness predicts greater recovery from negative emotion. Emotion 2012;12:875-81.
147. McCrae RR, Martin TA, Costa PT. Age trends and age norms for the NEO Personality Inventory-3 in adolescents and adults. Assessment 2005;12:363-73.
148. Soto CJ, John OP. Short and extra-short forms of the Big Five Inventory-2: the BFI-2-S and BFI-2-XS. J Res Personal 2017;68:69-81.
149. Gosling SD, Rentfrow PJ, Swann WB. A very brief measure of the Big-Five personality domains. J Res Personal 2003;37:504-28.
150. Karsten J, Penninx BWJH, Riese H et al. The state effect of depressive and anxiety disorders on big five personality traits. J Psychiatr Res 2012;46:644-50.
151. Watson D, Nus E, Wu KD. Development and validation of the Faceted Inventory of the Five-Factor Model (FI-FFM). Assessment 2019;26:17-44.
152. Quilty LC, Ayearst L, Chmielewski M et al. The psychometric properties of the Personality Inventory for DSM-5 in an APA DSM-5 field trial sample. Assessment 2013;20:362-9.
153. McGrath JJ, Lim CCW, Plana-Ripoll O et al. Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries. Epidemiol Psychiatr Sci 2020;29:e153.
154. de Jonge P, Wardenaar KJ, Lim CCW et al. The cross-national structure of mental disorders: results from the World Mental Health Surveys. Psychol Med 2018;48:2073-84.
155. Kotov R, Krueger RF, Watson D et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol 2017;126:454-77.
156. Maj M. ‘Psychiatric comorbidity’: an artefact of current diagnostic systems? Br J Psychiatry 2005;186:182-4.
157. Goodwin RD, Gorman JM. Psychopharmacologic treatment of generalized anxiety disorder and the risk of major depression. Am J Psychiatry 2002; 159:1935-7.
158. de Vries YA, Al-Hamzawi A, Alonso J et al. Childhood generalized specific phobia as an early marker of internalizing psychopathology across the life-span: results from the World Mental Health Surveys. BMC Med 2019;17:101.
159. Zimmerman M, Chelminski I. A scale to screen for DSM-IV Axis I disorders in psychiatric out-patients: performance of the Psychiatric Diagnostic Screening Questionnaire. Psychol Med 2006;36:1601-11 .
160. Tural U, Iosifescu DV. The prevalence of mitral valve prolapse in panic disorder: a meta-analysis. Psychosomatics 2019;60:393-401.
161. Bianchi Sanches SH, de Lima Osório F, Udina M et al. Anxiety and joint hypermobility association: a systematic review. Braz J Psychiatry 2012;34:S53-60.
162. Iljazi A, Ashina H, Al-Khazali HM et al. Post-traumatic stress disorder after traumatic brain injury – A systematic review and meta-analysis. Neurol Sci 2020;41:2737-46.
163. Chang K. Clinical evaluation of youth with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. J Child Adolesc Psychopharmacol 2015;25:3-13.
164. Roest AM, Martens EJ, de Jonge P et al. Anxiety and risk of incident coronary heart disease. J Am Coll Cardiol 2010;56:38-46.
165. Roest AM, Martens EJ, Denollet J et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med 2010;72:563-9.
166. Iozzia G, de Miranda Azevedo R, van der Harst P et al. Association of recognized and unrecognized myocardial infarction with depressive and anxiety disorders in 125,988 individuals: a report of the Lifelines Cohort Study. Psychosom Med 2020;82:736-43.
167. Momen NC, Plana-Ripoll O, Agerbo E et al. Association between mental disorders and subsequent medical conditions. N Engl J Med 2020;382:1721-31.
168. Muller JE, Koen L, Stein DJ. Anxiety and medical disorders. Curr Psychiatry Rep 2005;7:245-51.
169. Stein DJ, Benjet C, Gureje O et al. Integrating mental health with other non-communicable diseases. BMJ 2019;364:l295.
170 . Frith J, Solmi M, Wootton RE et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry 2020;19:360-80 .
171. Alberts NM, Hadjistavropoulos HD, Jones SL et al. The Short Health Anxiety Inventory: a systematic review and meta-analysis. J Anxiety Disord 2013;27:68-78.
172. Tyrer P. Recent advances in the understanding and treatment of health anxiety. Curr Psychiatry Rep 2018;20:49.
173. Frankovich J, Swedo S, Murphy T et al. Clinical management of pediatric acute-onset neuropsychiatric syndrome: Part II – Use of immunomodulatory therapies. J Child Adolesc Psychopharmacol 2017;27:574-93.
174. Mikolić A, Polinder S, Retel Helmrich IRA et al. Treatment for posttraumatic stress disorder in patients with a history of traumatic brain injury: a systematic review. Clin Psychol Rev 2019;73:101776.
175. McDowell CP, Dishman RK, Gordon BR et al. Physical activity and anxiety: a systematic review and meta-analysis of prospective cohort studies. Am J Prevent Med 2019;57:545-56.
176. Sarris J, Camfield D, Berk M. Complementary medicine, self-help, and life-style interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review. J Affect Disord 2012;138:213-21.
177. Trkulja V, Barić H. Current research on complementary and alternative medicine (CAM) in the treatment of anxiety disorders: an evidence-based review. In: Kim Y-K (ed). Anxiety disorders. Singapore: Springer, 2020:415-49.
178. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001;158:1568-78.
179. Low NCP, Cui L, Merikangas KR. Specificity of familial transmission of anxiety and comorbid disorders. J Psychiatr Res 2008;42:596-604.
180. Rougemont-Buecking A, Rothen S, Jeanprêtre N et al. Inter-informant agreement on diagnoses and prevalence estimates of anxiety disorders: direct interview versus family history method. Psychiatry Res 2008;157:211-23.
181. Weissman MM. Brief screening for family psychiatric history: the Family History Screen. Arch Gen Psychiatry 2000;57:675-82.
182 . Milne BJ, Caspi A, Harrington H et al. Predictive value of family history on severity of illness: the case for depression, anxiety, alcohol dependence, and drug dependence. Arch Gen Psychiatry 2009;66:738-47.
183. Brander G, Pérez-Vigil A, Larsson H et al. Systematic review of environmental risk factors for obsessive-compulsive disorder: a proposed roadmap from association to causation. Neurosci Biobehav Rev 2016;65:36-62.
184. Brook CA, Schmidt LA. Social anxiety disorder: a review of environmental risk factors. Neuropsychiatr Dis Treat 2008;4:123-43.
185. Norton AR, Abbott MJ. The role of environmental factors in the aetiology of social anxiety disorder: a review of the theoretical and empirical literature. Behav Change 2017;34:76-97.
186. Sareen J, Henriksen CA, Bolton SL et al. Adverse childhood experiences in relation to mood and anxiety disorders in a population-based sample of active military personnel. Psychol Med 2013;43:73-84.
187. Afifi TO, Mota NP, Dasiewicz P et al. Physical punishment and mental disorders: results from a nationally representative US sample. Pediatrics 2012;130:184-92.
188. Otowa T, York TP, Gardner CO et al. The impact of childhood parental loss on risk for mood, anxiety and substance use disorders in a population-based sample of male twins. Psychiatry Res 2014;220:404-9.
189. Taillieu TL, Brownridge DA, Sareen J et al. Childhood emotional maltreatment and mental disorders: results from a nationally representative adult sample from the United States. Child Abuse Neglect 2016;59:1-12.
190. Vrshek-Schallhorn S, Wolitzky-Taylor K, Doane LD et al. Validating new summary indices for the Childhood Trauma Interview: associations with first on-sets of major depressive disorder and anxiety disorders. Psychol Assess 2014;26:730-40.
191. Kessler RC, McLaughlin KA, Green JG et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry 2010;197:378-85.
192. Bifulco A, Brown GW, Harris TO. Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry 1994;35:1419-35.
193. Bifulco A, Bernazzani O, Moran PM et al. The Childhood Experience of Care and Abuse Questionnaire (CECA.Q): validation in a community series. Br J World Psychiatry 20:3 – October 2021 355 Clin Psychol 2005;44:563-81.
194. Bernstein DP, Stein JA, Newcomb MD et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Neglect 2003;27:169-90.
195. Louis JP, Wood AM, Lockwood G. Psychometric validation of the Young Parenting Inventory – Revised (YPI-R2): replication and extension of a commonly used parenting scale in schema therapy (ST) research and practice. PLoS One 2018;13:e0205605.
196. Young JE, Brown G. Young schema questionnaire. In: Young JE (ed). Cognitive therapy for personality disorders: a schema-focused approach, 2nd ed. Sarasota: Professional Resource Press/Professional Resource Exchange, 1994:63-76.
197. Lund C, Brooke-Sumner C, Baingana F et al. Social determinants of mental disorders and the sustainable development goals: a systematic review of reviews. Lancet Psychiatry 2018;5:357-69.
198. McLaughlin KA, Conron KJ, Koenen KC et al. Childhood adversity, adult stressful life events, and risk of past-year psychiatric disorder: a test of the stress sensitization hypothesis in a population-based sample of adults. Psychol Med 2010;40:1647-58.
199. Kendler KS, Baker JH. Genetic influences on measures of the environment: a systematic review. Psychol Med 2007;37:615-26.
200. Kendler KS, Myers J, Prescott CA. The etiology of phobias: an evaluation of the stress-diathesis model. Arch Gen Psychiatry 2002;59:
201. Lau JYF, Gregory AM, Goldwin MA et al. Assessing gene-environment interactions on anxiety symptom subtypes across childhood and adolescence. Dev Psychopathol 2007;19:1129-46.
202. Keers R, Coleman JRI, Lester KJ et al. A genome-wide test of the differential susceptibility hypothesis reveals a genetic predictor of differential response to psychological treatments for child anxiety disorders. Psychother Psychosom 2016;85:146-58.
203. Brown GW, Harris TO, Hepworth C. Life events and endogenous depression. A puzzle reexamined. Arch Gen Psychiatry 1994;51:525-34.
204. Hammen C, Ellicott A, Gitlin M et al. Sociotropy/autonomy and vulnerabilityto specific life events in patients with unipolar depression and bipolar disorders. J Abnorm Psychol 1989;98:154-60.
205. Dohrenwend BS, Askenasy AR, Krasnoff L et al. Exemplification of a method for scaling life events: the PERI Life Events Scale. J Health Soc Behav 1978;19:205-29.
206. Brugha TS, Cragg D. The List of Threatening Experiences: the reliability and validity of a brief life events questionnaire. Acta Psychiatr Scand 1990;82:77-81.
207. Butjosa A, Gómez-Benito J, Myin-Germeys I et al. Development and validation of the Questionnaire of Stressful Life Events (QSLE).
J Psychiatr Res 2017;95:213-23.
208. Williams DR, Gonzalez HM, Williams S et al. Perceived discrimination, race and health in South Africa. Soc Sci Med 2008;67:441-52.
209. Shippee ND, Shah ND, May CR et al. Cumulative complexity: a functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol 2012;65:1041-51.
210. Faravelli C, Lo Sauro C, Lelli L et al. The role of life events and HPA axis in anxiety disorders: a review. Curr Pharm Des 2012;18:5663-74.
211. Ehlers A. Somatic symptoms and panic attacks: a retrospective study of learning experiences. Behav Res Ther 1993;31:269-78.
212. Fredrickson BL, Joiner T. Positive emotions trigger upward spirals toward emotional well-being. Psychol Sci 2002;13:172-5.
213. Sewart AR, Zbozinek TD, Hammen C et al. Positive affect as a buffer between chronic stress and symptom severity of emotional disorders. Clin Psychol Sci 2019;7:914-27.
214. Dooley B, Fitzgerald A, Giollabhui NM. The risk and protective factors associated with depression and anxiety in a national sample of Irish adolescents. Irish J Psychol Med 2015;32:93-105.
215. Zimmermann M, Chong AK, Vechiu C et al. Modifiable risk and protective factors for anxiety disorders among adults: a systematic review. Psychiatry Res 2020;285:112705.
216. van Harmelen A-L, Gibson JL, St Clair MC et al. Friendships and family support reduce subsequent depressive symptoms in at-risk adolescents. PLoS One 2016;11:e0153715.
217. Metts A, Zinbarg R, Hammen C et al. Extraversion and interpersonal support as risk, resource, and protective factors in the prediction of unipolar mood and anxiety disorders. J Abnorm Psychol 2021;130:47-59.
218. Iemmi V, Bantjes J, Coast E et al. Suicide and poverty in low-income and middle-income countries: a systematic review. Lancet Psychiatry 2016;3:774-83.
219. Milner A, Page A, LaMontagne AD. Cause and effect in studies on unemployment, mental health and suicide: a meta-analytic and conceptual review. Psychol Med 2014;44:909-17.
220. Mollison E, Chaplin E, Underwood L et al. A review of risk factors associated with suicide in adults with intellectual disability. Adv Ment Health Intellect Disabil 2014;8:302-8.
221. Austad S, Nesse RM. Good reasons for bad feelings: insights from the frontier of evolutionary psychiatry. Evol Med Public Health 2020;2020:28-9.
222. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Personal Soc Psychol 1988;54:1063-70.
223. Rosenberg M. Society and the adolescent self-image. Princeton: Princeton University Press, 1965.
224. Cella D, Yount S, Rothrock N et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH roadmap cooperative group during its first two years. Med Care 2007;45(Suppl. 1):S3-11.
225. Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. Health Qual Life Outcomes 2011;9:8.
226. Connor KM, Davidson JRT. Development of a new resilience scale: the Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety 2003;18:76-82.
227. Campbell-Sills L, Stein MB. Psychometric analysis and refinement of the Connor-Davidson Resilience Scale (CD-RISC): validation of a 10-item measure of resilience. J Trauma Stress 2007;20:1019-28.
228. Smith BW, Dalen J, Wiggins K et al. The brief resilience scale: assessing the ability to bounce back. Int J Behav Med 2008;15:194-200.
229. Zimet GD, Powell SS, Farley GK et al. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Personal Assess 1990;55:610-7.
230. Sherbourne CD, Stewart A. The MOS Social Support Survey. Santa Monica: RAND Corporation, 1993.
231. Lazarus RS, Folkman S. Stress, appraisal, and coping. Berlin: Springer, 1984.
232. Carver CS. You want to measure coping but your protocol’s too long: consider the brief COPE. Int J Behav Med 1997;4:92-100.
233. Craske MG, Burton T, Barlow DH. Relationships among measures of communication, marital satisfaction and exposure during couples treatment of agoraphobia. Behav Res Ther 1989;27:131-40.
234. Thompson-Hollands J, Edson A, Tompson MC et al. Family involvement in the psychological treatment of obsessive-compulsive disorder: a meta-analysis. J Fam Psychol 2014;28:287-98.
235. Zbozinek TD, Craske MG. The role of positive affect in enhancing extinction learning and exposure therapy for anxiety disorders. J Exp Psychopathol 2017;8:13-39.
236. Craske MG, Meuret AE, Ritz T et al. Treatment for anhedonia: a neuroscience driven approach. Depress Anxiety 2016;33:927-38.
237. Craske MG, Treanor M, Dour H et al. Positive affect treatment for depression and anxiety: a randomized clinical trial for a core feature of anhedonia. J Consult Clin Psychol 2019;87:457-71.
238. Lindsay EK, Chin B, Greco CM et al. How mindfulness training promotes positive emotions: dismantling acceptance skills training in two randomized controlled trials. J Pers Soc Psychol 2018;115:944-73.
239. Bar-Haim Y, Lamy D, Pergamin L et al. Threat-related attentional bias in anxious and nonanxious individuals: a meta-analytic study. Psychol Bull 2007;133:1-24.
240. Khalsa SS, Adolphs R, Cameron OG et al. Interoception and mental health: a roadmap. Biol Psychiatry Cogn Neurosci Neuroimaging 2018;3:501-13.
241. Paulus MP, Stein MB. Interoception in anxiety and depression. Brain Struct Funct 2010;214:451-63.
242. Koster EHW, Crombez G, Verschuere B et al. Components of attentional bias to threat in high trait anxiety: facilitated engagement, impaired disengagement, and attentional avoidance. Behav Res Ther 2006;44:1757-71.
243. Fox E, Russo R, Bowles R et al. Do threatening stimuli draw or hold visual attention in subclinical anxiety? J Experiment Psychol Gen 2001;130:681-700.
244. Ouimet AJ, Gawronski B, Dozois DJA. Cognitive vulnerability to anxiety: a review and an integrative model. Clin Psychol Rev 2009;29:459-70.
245. Hirsch CR, Meeten F, Krahé C et al. Resolving ambiguity in emotional disorders: the nature and role of interpretation biases. Annu Rev Clin Psychol 2016;12:281-305.
246. Bernstein A, Zvolensky MJ. Anxiety sensitivity: selective review of promising research and future directions. Expert Rev Neurother 2007;7:97-101.
247. Derryberry D, Reed MA. Anxiety-related attentional biases and their regulation by attentional control. J Abnorm Psychol 2002;111:225-36.
248. Amin N, Foa EB, Coles ME. Negative interpretation bias in social phobia. Behav Res Ther 1998;36:945-57.
249. Myers SG, Fisher PL, Wells A. Belief domains of the Obsessive Beliefs Questionnaire-44 (OBQ-44) and their specific relationship with obsessive-compulsive symptoms. J Anxiety Disord 2008;22:475-84.
250. Mehling WE, Acree M, Stewart A et al. The Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2). PLoS One 2018;13:e0208034.
251. Taylor S, Zvolensky MJ, Cox BJ et al. Robust dimensions of anxiety sensitivity: development and initial validation of the Anxiety Sensitivity Index-3. Psychol Assess 2007;19:176-88.
252. Hicks TV, Leitenberg H, Barlow DH et al. Physical, mental, and social catastrophic cognitions as prognostic factors in cognitive-behavioral and pharmacological treatments for panic disorder. J Consult Clin Psychol 2005;73:506-14.
253. Wells A. Metacognitive therapy for anxiety and depression. New York: Guilford, 2009.
254. Knowles MM, Foden P, El-Deredy W et al. A systematic review of efficacy of the attention training technique in clinical and nonclinical samples. J Clin Psychol 2016;72:999-1025.
255. Cristea IA, Kok RN, Cuijpers P. Efficacy of cognitive bias modification interventions in anxiety and depression: meta-analysis. Br J Psychiatry 2015;206:7-16.
256. Heeren A, Mogoas ̧e C, Philippot P et al. Attention bias modification for social anxiety: a systematic review and meta-analysis. Clin Psychol Rev 2015;40:76-90.
257. Smits JAJ, Rosenfield D, McDonald R et al. Cognitive mechanisms of social anxiety reduction: an examination of specificity and temporality. J Consult Clin Psychol 2006;74:1203-12.
258. Rapee RM, Gaston JE, Abbott MJ. Testing the efficacy of theoretically derived improvements in the treatment of social phobia. J Consult Clin Psychol 2009;77:317-27.
259. Hedman E, Mörtberg E, Hesser H et al. Mediators in psychological treatment of social anxiety disorder: individual cognitive therapy compared to cognitive behavioral group therapy. Behav Res Ther 2013;51:696-705.
260. Maj M, van Os J, De Hert M et al. The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry 2021;20:4-33.
261. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. World Psychiatry 2019;18:276-85.
262. Lorimer B, Kellett S, Nye A et al. Predictors of relapse and recurrence following cognitive behavioural therapy for anxiety-related disorders: a systematic review. Cogn Behav Ther 2021;50:1-18.
263. de Beurs E, Fried E. From mandating common measures to mandating common metrics: a plea to harmonize measurement results. PsyArXiv 2021;10. 31234.
264. Wolpert M. Funders agree first common metrics for mental health science. https://www.linkedin.com.
265. Hughes KL, Clarke M, Williamson PR. A systematic review finds Core Outcome Set uptake varies widely across different areas of health. J Clin Epidemiol 2021;129:114-23.
266. Obbarius A, van Maasakkers L, Baer L et al. Standardization of health outcomes assessment for depression and anxiety: recommendations from the ICHOM Depression and Anxiety Working Group. Qual Life Res 2017;26:3211-25.
267. Prenoveau JM, Zinbarg RE, Craske MG et al. Testing a hierarchical model of anxiety and depression in adolescents: a tri-level model.
J Anxiety Disord 2010;24:334-44.
268. Naragon-Gainey K, Prenoveau JM, Brown TA et al. A comparison and integration of structural models of depression and anxiety in a clinical sample: support for and validation of the tri-level model. J Abnorm Psychol